Author

Laurent Peyrin-Biroulet

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Laurent Peyrin-Biroulet  et al.

TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM
TREATMENT PATTERNS AMONG PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE RECEIVING BIOLOGIC THERAPY IN FRANCE, GERMANY AND THE UNITED KINGDOM

Laurent Peyrin-Biroulet  et al.

IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Laurent Peyrin-Biroulet  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Laurent Peyrin-Biroulet  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Laurent Peyrin-Biroulet  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Laurent Peyrin-Biroulet  et al.

ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY
ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY

Laurent Peyrin-Biroulet  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Laurent Peyrin-Biroulet  et al.

REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY
REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY

Laurent Peyrin-Biroulet  et al.

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION
EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Laurent Peyrin-Biroulet  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Laurent Peyrin-Biroulet  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY
IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY

Laurent Peyrin-Biroulet  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

Laurent Peyrin-Biroulet  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Laurent Peyrin-Biroulet  et al.

ULTRASOUND REMISSION AFTER BIOLOGIC INDUCTION PREDICTS LONG-TERM ENDOSCOPIC REMISSION IN CROHN’S DISEASE
ULTRASOUND REMISSION AFTER BIOLOGIC INDUCTION PREDICTS LONG-TERM ENDOSCOPIC REMISSION IN CROHN’S DISEASE

Laurent Peyrin-Biroulet  et al.

Item 61 - 80 / 115
1 2 3
4
5 6